# Congenital Human Cytomegalovirus and the Complement System

## TL;DR

This paper reviews how the complement system may influence congenital HCMV infections and related complications in newborns.

## Contribution

The paper proposes a novel hypothesis that dysregulated complement activity contributes to HCMV-related pathogenesis in fetuses.

## Key findings

- The complement system plays dual roles in containing HCMV and potentially causing tissue damage.
- HCMV may disrupt complement regulation during pregnancy, leading to neurodevelopmental issues.
- Targeting complement pathways could offer new therapeutic strategies for HCMV.

## Abstract

Congenital human cytomegalovirus (HCMV) infection is the most common vertically transmitted viral infection, and it affects 1 in 200 live births worldwide. While neonates are often asymptomatic at birth, congenital HCMV infection can result in long-term complications, including microcephaly, sensorineural hearing loss, and neurodevelopmental abnormalities. Developing antiviral strategies for the treatment and prevention of congenital HCMV infections is a global public health priority. However, licensed anti-HCMV vaccines are not yet available, and therapeutic options for use during pregnancy remain limited. The complement system is a crucial component of the innate immune system that plays essential roles in both fetal development and maternal defense against infectious pathogens. In cases of congenital HCMV infection, complement may contribute to the successful containment of the virus, but dysregulation and overactivation could concurrently drive tissue-damaging inflammation. This review discusses the known roles of the complement system in fetal development and in HCMV pathogenesis and synthesizes existing research to develop the hypothesis that a dysregulated complement system is a key mechanism in the development of congenital HCMV-related pathogenesis and neurodevelopmental sequelae. We explore how HCMV may perturb the complement system during pregnancy and use one inhibitor example to illustrate the broader potential of targeting complement in limiting disease.